Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays

scientific article published on 12 January 2019

Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3390/TOXINS11010035
P932PMC publication ID6356430
P698PubMed publication ID30642048

P50authorSérgio Luiz DalmoraQ91040954
P2093author name stringBruna Xavier
Maurício Elesbão Walter
Rafaela Ferreira Perobelli
Francielle Santos da Silva
P2860cites workProperties and use of botulinum toxin and other microbial neurotoxins in medicineQ23833526
Assessing the Immunogenicity of BiopharmaceuticalsQ26751485
Characterizing biological products and assessing comparability following manufacturing changes.Q30344134
Quantitative mass spectrometry for bacterial protein toxins--a sensitive, specific, high-throughput tool for detection and diagnosis.Q33845862
Clinical uses of botulinum neurotoxins: current indications, limitations and future developmentsQ36395728
Progress in cell based assays for botulinum neurotoxin detectionQ36818335
Bioassays for evaluation of medical products derived from bacterial toxinsQ38014992
Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassaysQ38056721
Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their AggregatesQ38078925
The Expanding Therapeutic Utility of Botulinum Neurotoxins.Q55105284
Cell-Based Reporter Release Assay to Determine the Potency of Proteolytic Bacterial NeurotoxinsQ58762547
Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the InternationaQ73071507
Validation of in vitro assays for botulinum toxin: a case studyQ73194608
Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methodsQ90503604
Methods and difficulties in detection of Clostridium botulinum and its toxins.Q38203898
Botulinum toxin A, brain and painQ38219087
Botulinum neurotoxins: genetic, structural and mechanistic insights.Q38224215
The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxinsQ38340501
Analysis of streptokinase by validated liquid chromatography methods and correlation with an in vitro bioassayQ38435106
Botulinum toxin: State of the art.Q38668149
Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell lineQ39159847
Botulinum Neurotoxins: Biology, Pharmacology, and ToxicologyQ39207459
Development of a Cell-Based Functional Assay for the Detection of Clostridium botulinum Neurotoxin Types A and E.Q39243951
Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impuritiesQ39703051
A chip-based assay for botulinum neurotoxin A activity in pharmaceutical preparationsQ41448985
The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting.Q42915094
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A productsQ43185582
A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A.Q43999920
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjecttoxicologyQ7218
reversed-phase chromatographyQ645497
size-exclusion chromatographyQ1617865
P304page(s)35
P577publication date2019-01-12
P1433published inToxinsQ15724569
P1476titleContent/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays
P478volume11

Reverse relations

Q91994510Rapid Detection of Botulinum Neurotoxins-A Reviewcites workP2860

Search more.